 |
160 Products |  |
813 Diseases | | 160 Products |
|
1618 Trials |  |
78436 News |  |
| «12...894895896897898899900901902903904...910911» |
- Vectibix (panitumumab) / Amgen
Trial termination: Panitumumab and Irinotecan for Malignant Gliomas (clinicaltrials.gov) - Dec 3, 2012
P2, N=16, Terminated, Sponsor: Annick Desjardins
Active, not recruiting --> Terminated; study did not reach benchmark efficacy rule at 16 subjects
- Vectibix (panitumumab) / Amgen
Enrollment change: Panitumumab and Irinotecan for Malignant Gliomas (clinicaltrials.gov) - Dec 3, 2012
P2, N=16, Terminated, Sponsor: Annick Desjardins
Active, not recruiting --> Terminated; study did not reach benchmark efficacy rule at 16 subjects N=32 --> 16
- New P4 trial: A randomised controlled trial to compare withdrawal of therapy versus continuing therapy in low disease states in psoriatic arthritis (EUDRACT) - Dec 3, 2012
P4, N=30, Ongoing, Sponsor: University of Leeds
- | Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Dec 3, 2012
P2, N=25, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
- Neulasta (pegfilgrastim) / Roche
Enrollment change: Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors (clinicaltrials.gov) - Dec 2, 2012
P2, N=55, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=32 --> 16 N=41 --> 55
- |||||||||| Ibrance (palbociclib) / Pfizer
New P3 trial, IO biomarker: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) (clinicaltrials.gov) - Dec 2, 2012
P3, N=450, Recruiting, Sponsor: Pfizer
- ||||| Imlygic (talimogene laherparepvec) / Amgen
New P1/2 trial: Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Dec 2, 2012
P1/2, N=149, Recruiting, Sponsor: Amgen
- melphalan / Generic mfg., amifostine / Generic mfg.
Trial termination: Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation (clinicaltrials.gov) - Nov 29, 2012
P1, N=8, Terminated, Sponsor: Eastern Cooperative Oncology Group
N=41 --> 55 Active, not recruiting --> Terminated; Slow accrual and changes in clinical practice
- melphalan / Generic mfg., amifostine / Generic mfg.
Enrollment change: Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation (clinicaltrials.gov) - Nov 29, 2012
P1, N=8, Terminated, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Terminated; Slow accrual and changes in clinical practice N=46 --> 8
- | Krystexxa (pegloticase) / Amgen
New P1 trial: Study to Assess Pegloticase (KRYSTEXXA (clinicaltrials.gov) - Nov 29, 2012
P1, N=12, Completed, Sponsor: Savient Pharmaceuticals
- epirubicin / Generic mfg.
Trial completion, Surgery: Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer (clinicaltrials.gov) - Nov 29, 2012
P2, N=15, Completed, Sponsor: Case Comprehensive Cancer Center
N=46 --> 8 Active, not recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
New P4 trial: Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis (clinicaltrials.gov) - Nov 28, 2012
P4, N=41, Terminated, Sponsor: Amgen
- | omecamtiv mecarbil (AMG 423) / Amgen, Servier
New P1 trial: Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency (clinicaltrials.gov) - Nov 28, 2012
P1, N=13, Completed, Sponsor: Amgen
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change, Surgery: Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Nov 27, 2012
P3, N=15, Terminated, Sponsor: Radiation Therapy Oncology Group
Active, not recruiting --> Completed N=240 --> 15
- |||| Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Enrollment open: NOLAN: Naproxen or Loratadine and Neulasta (clinicaltrials.gov) - Nov 27, 2012
P2, N=600, Recruiting, Sponsor: Amgen
N=240 --> 15 Not yet recruiting --> Recruiting
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Enrollment closed: Reversing Type 1 Diabetes After it is Established (clinicaltrials.gov) - Nov 27, 2012
P1/2, N=25, Active, not recruiting, Sponsor: University of Florida
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || AMG 208 / Amgen
Enrollment change, Metastases: A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Nov 26, 2012
P1, N=54, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting N=102 --> 54
- cisplatin / Generic mfg., docetaxel / Generic mfg.
Enrollment change, Surgery: SWOG-S0332: Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 26, 2012
P3, N=19, Terminated, Sponsor: Radiation Therapy Oncology Group
N=102 --> 54 N=574 --> 19
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo (clinicaltrials.gov) - Nov 26, 2012
P4, N=90, Active, not recruiting, Sponsor: Medical University of Vienna
- || AMG 208 / Amgen
Enrollment closed, Metastases: A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Nov 26, 2012
P1, N=54, Active, not recruiting, Sponsor: Amgen
N=574 --> 19 Recruiting --> Active, not recruiting
- |||||||||| Procysbi (cysteamine bitartrate delayed release) / Amgen
New P3 trial: Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis (clinicaltrials.gov) - Nov 25, 2012
P3, N=60, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment open: Allogeneic Stem Cell Transplant for CLL (clinicaltrials.gov) - Nov 25, 2012
P1/2, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| trebananib (AMG 386) / Amgen, Avastin (bevacizumab) / Roche
Enrollment open: Amgen 386 for Recurrent Glioblastoma (clinicaltrials.gov) - Nov 25, 2012
P1/2, N=86, Recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Suspended --> Recruiting
- ||||| Prolia (denosumab) / Amgen
New P4 trial: Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Nov 22, 2012
P4, N=643, Active, not recruiting, Sponsor: Amgen
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial termination: SubCutaneous (SC) Versus Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients (clinicaltrials.gov) - Nov 20, 2012
P4, N=120, Terminated, Sponsor: Rabin Medical Center
Suspended --> Recruiting Recruiting --> Terminated; Physycians' refusal to continue the study
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: SubCutaneous (SC) Versus Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients (clinicaltrials.gov) - Nov 20, 2012
P4, N=120, Terminated, Sponsor: Rabin Medical Center
Recruiting --> Terminated; Physycians' refusal to continue the study N=200 --> 120
- Rituxan (rituximab) / Roche
Enrollment change: Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Nov 20, 2012
P2, N=39, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=200 --> 120 N=30 --> 39
- | lenalidomide / Generic mfg.
New P4 trial: Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma (clinicaltrials.gov) - Nov 20, 2012
P4, N=114, Recruiting, Sponsor: Columbia University
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier
Clinical: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 20, 2012
P3, N=195, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 39 Completed --> Active, not recruiting
- || Blincyto (blinatumomab) / Astellas, Amgen
Enrollment change: Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL (clinicaltrials.gov) - Nov 19, 2012
P1, N=76, Completed, Sponsor: Amgen Research (Munich) GmbH
Completed --> Active, not recruiting N=60 --> 76
- | Decadron (dexamethasone) / Merck (MSD)
Enrollment change: Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma (clinicaltrials.gov) - Nov 19, 2012
P2, N=38, Completed, Sponsor: Weill Medical College of Cornell University
N=60 --> 76 N=60 --> 38
- Enbrel (etanercept) / Pfizer, Amgen, Rituxan (rituximab) / Roche
New P2 trial: Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome (clinicaltrials.gov) - Nov 19, 2012
P2, N=15, Recruiting, Sponsor: Haukeland University Hospital
- | Enbrel (etanercept) / Pfizer, Amgen
New P2 trial: Limitation of Ischemic Injury of a Kidney Stored in Machine Perfusion in Hypothermia - Evaluation of the Impact on Kidney Allograft Function (clinicaltrials.gov) - Nov 19, 2012
P2, N=100, Recruiting, Sponsor: Medical University of Warsaw
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed, Minimal residual disease: Phase II Study of the BiTE (clinicaltrials.gov) - Nov 19, 2012
P2, N=21, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
N=60 --> 38 Completed --> Active, not recruiting
- ||| Blincyto (blinatumomab) / Astellas, Amgen
Trial completion: Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL (clinicaltrials.gov) - Nov 19, 2012
P1, N=76, Completed, Sponsor: Amgen Research (Munich) GmbH
Completed --> Active, not recruiting Active, not recruiting --> Completed
- | Decadron (dexamethasone) / Merck (MSD)
Trial completion: Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma (clinicaltrials.gov) - Nov 19, 2012
P2, N=38, Completed, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Climara (estradiol) / Bausch Health, Bayer, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Biomarker, Trial withdrawal: Optimizing Ovulation Induction in the Poor Responder (clinicaltrials.gov) - Nov 18, 2012
P=N/A, N=0, Withdrawn, Sponsor: Duke University
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Climara (estradiol) / Bausch Health, Bayer, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Biomarker, Enrollment change: Optimizing Ovulation Induction in the Poor Responder (clinicaltrials.gov) - Nov 18, 2012
P=N/A, N=0, Withdrawn, Sponsor: Duke University
Not yet recruiting --> Withdrawn N=100 --> 0
- |||||||||| Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
New P3 trial: reSURFACE 2: A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) (clinicaltrials.gov) - Nov 18, 2012
P3, N=1050, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||| rilotumumab (AMG 102) / Amgen
Enrollment open, Metastases: RILOMET-1: First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov) - Nov 18, 2012
P3, N=450, Recruiting, Sponsor: Amgen
N=100 --> 0 Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial withdrawal: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia (clinicaltrials.gov) - Nov 15, 2012
P1/2, N=0, Withdrawn, Sponsor: Columbia University
Not yet recruiting --> Recruiting Completed --> Withdrawn
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia (clinicaltrials.gov) - Nov 15, 2012
P1/2, N=0, Withdrawn, Sponsor: Columbia University
Completed --> Withdrawn N=43 --> 0
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, Metastases: Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm (clinicaltrials.gov) - Nov 15, 2012
P2, N=50, Active, not recruiting, Sponsor: University of Washington
N=43 --> 0 Recruiting --> Active, not recruiting
- | cisplatin / Generic mfg., vinblastine / Generic mfg.
Trial completion: S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma (clinicaltrials.gov) - Nov 14, 2012
P3, N=432, Completed, Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Prolia (denosumab) / Amgen
Trial initiation date, Tumor cell: Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer (clinicaltrials.gov) - Nov 13, 2012
P2, N=45, Recruiting, Sponsor: Hope Rugo, MD
Active, not recruiting --> Completed Initiation date: Jun 2012 --> Nov 2012
- Prolia (denosumab) / Amgen
Enrollment open, Tumor cell: Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer (clinicaltrials.gov) - Nov 13, 2012
P2, N=45, Recruiting, Sponsor: Hope Rugo, MD
Initiation date: Jun 2012 --> Nov 2012 Not yet recruiting --> Recruiting
- ||||| Neulasta (pegfilgrastim) / Roche
Enrollment closed, Metastases: PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study (clinicaltrials.gov) - Nov 13, 2012
P3, N=847, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Promacta (eltrombopag) / Novartis
Enrollment closed: Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Nov 13, 2012
P2, N=12, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Actimmune (interferon gamma-1 b) / Clinigen, Amgen
Enrollment open, IO biomarker: The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis (clinicaltrials.gov) - Nov 11, 2012
P3, N=20, Recruiting, Sponsor: Radboud University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- docetaxel / Generic mfg.
Trial completion, Metastases: Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Nov 11, 2012
P1/2, N=30, Completed, Sponsor: University of Michigan Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed